Related references
Note: Only part of the references are listed.Mutation S462P in the PCSK9 gene reduces secretion of mutant PCSK9 without affecting the autocatalytic cleavage
Jamie Cameron et al.
ATHEROSCLEROSIS (2009)
Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor
Christopher J. Duff et al.
BIOCHEMICAL JOURNAL (2009)
Mutations and Polymorphisms in the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene in Cholesterol Metabolism and Disease
Marianne Abifadel et al.
HUMAN MUTATION (2009)
Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants
Matthew J. Bottomley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells
Markey C. McNutt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants
Sekar Kathiresan et al.
NATURE GENETICS (2009)
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
Joyce C. Y. Chan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo
Robert J. Schmidt et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide
LiXin Shan et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Annexin A2 Is a C-terminal PCSK9-binding Protein That Regulates Endogenous Low Density Lipoprotein Receptor Levels
Gaetan Mayer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Functional analysis of sites within PCSK9 responsible for hypercholesterolemia
Shilpa Pandit et al.
JOURNAL OF LIPID RESEARCH (2008)
Plasma PCSK9 preferentially reduces liver LDL receptors in mice
Aldo Grefhorst et al.
JOURNAL OF LIPID RESEARCH (2008)
The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies
Christine Rothe et al.
JOURNAL OF MOLECULAR BIOLOGY (2008)
Molecular basis for LDL receptor recognition by PCSK9
Hyock Joo Kwon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor
Da-Wei Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
Maria Frank-Kamenetsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
PCSK9 and LDL cholesterol: unravelling the target to design the bullet
Philippe Costet et al.
TRENDS IN BIOCHEMICAL SCIENCES (2008)
The self-inhibited structure of full-length PCSK9 at 1.9 Å reveals structural homology with resistin within the C-terminal domain
Eric N. Hampton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation
Timothy S. Fisher et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR
Nasha Nassoury et al.
TRAFFIC (2007)
The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol
Derek E. Piper et al.
STRUCTURE (2007)
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
David Cunningham et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2007)
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice
Thomas A. Lagace et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy
KE Berge et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A spectrum of PCSK9 Alleles contributes to plasma levels of low-density lipoprotein cholesterol
IK Kotowski et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
C Jonathan et al.
NATURE GENETICS (2005)
A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree
KM Timms et al.
HUMAN GENETICS (2004)
Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3
R Rauchenberger et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
Share Paper
